Theravance Biopharma TBPH Accounts Payable

Accounts Payable at other companies

Gyre Therapeutics, Inc.GYRE

$1.24M+1,641%

Rigel PharmaceuticalsRIGL

$4.49M+13.5%

LQD

Liquidia CorporationLQDA

$10.98M+26.6%

United TherapeuticsUTHR

$497.8M+15.2%

Royalty PharmaRPRX

$35.57M+76.0%

Zevra Therapeutics, Inc.ZVRA

$13.96M-11.9%

FAQ

What is Theravance Biopharma's accounts payable?

Theravance Biopharma (TBPH) reported accounts payable of $652K in Q2 2026.

How has Theravance Biopharma's accounts payable changed year-over-year?

Theravance Biopharma's accounts payable decreased by 61.1% year-over-year, from $1.68M to $652K.

What is the long-term trend for Theravance Biopharma's accounts payable?

Over 5 years (2020 to 2025), Theravance Biopharma's accounts payable has grown at a -17.6% compound annual growth rate (CAGR), from $6.78M to $2.57M.

What does accounts payable mean?

Amounts owed to suppliers and vendors for goods and services received but not yet paid. A primary source of short-term trade financing.